Vertex, GSK start Phase III HIV study

VRTX and partner GlaxoSmithKline (GSK; LSE:GSK) began a third open-label international Phase III study of GW433908 ( VX-175), a prodrug of the companies' Agenerase amprenavir HIV protease inhibitor, t...